Clinical Trial

Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Study acronym: BASA
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-05-18; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2023-08-23
Trial Details
NCT Number NCT05868525
Lead Sponsor Loma Linda University
Conditions Blunt Cerebrovascular Injury
Enrollment 98 participants
Start Date 2023-08-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-30